Edgewise Therapeutics Inc (EWTX)
17.51
0.00 (0.00%)
USD |
NASDAQ |
Jun 17, 13:27
Edgewise Therapeutics Cash from Financing (Quarterly): 241.07M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 241.07M |
| December 31, 2023 | 52.99M |
| September 30, 2023 | -0.211M |
| June 30, 2023 | 0.369M |
| March 31, 2023 | 0.021M |
| December 31, 2022 | -0.303M |
| September 30, 2022 | 129.69M |
| June 30, 2022 | 0.179M |
| March 31, 2022 | 0.073M |
| Date | Value |
|---|---|
| December 31, 2021 | 0.293M |
| September 30, 2021 | 0.037M |
| June 30, 2021 | -0.896M |
| March 31, 2021 | 186.95M |
| December 31, 2020 | 95.00M |
| September 30, 2020 | 25.14M |
| June 30, 2020 | 0.135M |
| March 31, 2020 | 0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.896M
Minimum
Jun 2021
241.07M
Maximum
Mar 2024
42.97M
Average
0.179M
Median
Jun 2022
Cash from Financing (Quarterly) Benchmarks
| Pfizer Inc | -4.931B |
| Alnylam Pharmaceuticals Inc | 28.91M |
| Catalyst Pharmaceuticals Inc | 141.05M |
| Cytokinetics Inc | 103.79M |
| Amicus Therapeutics Inc | -13.31M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -28.60M |
| Cash from Investing (Quarterly) | -268.31M |
| Free Cash Flow | -99.39M |
| Free Cash Flow Per Share (Quarterly) | -0.33 |
| Free Cash Flow Yield | -8.13% |